Dr. Vaagn Andikyan 

Gynecologic Oncology
Smilow Cancer Hospital at Yale New Haven
New Haven, CT 06511
View Contact Information

Schedule a Conversation with a HIPEC Surgeon

The surgeon or staff member will make their best effort to call you at your requested time. If they become unavailable you will receive a text.

Fill out my online form.

Board Certified

Board certification by an ABMS Member Board is the premier, independently assessed credential attainable in medicine today.

Dr. Vaagn Andikyan is affiliated with Smilow Cancer Hospital at Yale New Haven.

Fellowship Experience

  • Icahn School of Medicine at Mount Sinai
  • Memorial Sloan-Kettering Cancer Center

Additional Information

Dr. Andikyan is currently an Assistant Professor of Obstetrics, Gynecology & Reproductive Sciences at Yale School of Medicine. Focused on giving women perspective and hope to overcome the challenges of a cancer diagnosis, Dr. Andikyan offers medical expertise and emotional support for patients with endometrial, ovarian, cervical, and vulvar cancer. His devotion as a physician contributes to his reputation with patients as well as colleagues.

Dr. Andikyan earned his medical degree from I.M. Sechenov Moscow Medical Academy in 2002. He completed his Residency at SUNY Downstate Medical Center and Fellowships at Icahn School of Medicine of Mount Sinai & Memorial Sloan-Kettering Cancer Center. Board certified in Gynecologic Oncology, he holds a membership to the Society of Gynecologic Oncology and is a reviewer for the Journal of Gynecologic Oncology Case Reports.

Dr. Andikyan is well-versed in minimally invasive surgery, including laparoscopic and robotic techniques to treat benign and malignant conditions. His expertise includes debulking surgery, sentinel lymph node dissection, and surgery for vulvar cancer. Additionally, he provides compassionate care with chemotherapy and surveillance.

With a strong interest in HIPEC, Dr. Andikyan is not only actively engaged in HIPEC research but also the author of several publications on this topic. He has designed and implemented clinical trials; evaluating the role of HIPEC in recurrent ovarian cancer.